· Original article
Copart acquisition of ACV closes at $10.50 per share
The Copart acquisition of ACV Auctions closed on October 16, 2026, at $10.50 per share in cash, with about $1.8 billion paid to acquire control.
FINANCEVELIX / News
Equities & companies · Page 71
Equities & companies
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
Read the original source and publication date in each article.
Equities & companies
RSSResults: 1,920 · Page 71 / 160
· Original article
Nike India campus planned as part of global operating overhaul
Nike India campus plans form part of a global overhaul, with regional changes expected in fiscal 2028 and workforce decisions beginning in 2027.
· Original article
Omeros stock falls 12% after European narsoplimab setback
Omeros stock fell 12.03% intraday on October 16, 2026, after an EMA committee reaffirmed its negative opinion on narsoplimab following re-examination.
· Original article
Prudential Japan suspension cuts Q3 operating income by $140M
Prudential Japan suspension reduced estimated Q3 operating income by $140 million, with new-business restrictions extending through January 2027.
· Original article
Nucor shares rise 3.1% as September industrial output strengthens
Nucor shares gained 3.1% on October 16, 2026, as U.S. industrial output rose 0.7% in September, while major Wall Street indexes closed mixed.
· Original article
Nucor earnings outlook strengthens as steel prices rise
Nucor earnings guidance points to stronger third-quarter profit as steel prices rise, though higher costs and weaker raw materials limit the benefit.
· Original article
IDEXX stock gains 1.96% but remains lower over three months
IDEXX stock rose to $557.90 in an October 16, 2026 snapshot, while its earlier annual results provide context on recurring diagnostics growth.
· Original article
Rhythm coverage starts at William Blair with Outperform
Rhythm coverage begins with an Outperform rating at William Blair, while the firm's later announcement confirms its broader biotech research expansion.
· Original article
KVB credit growth target set at 18–20% for FY27
KVB credit growth guidance targets 18–20% in FY27, led by retail, agriculture and small businesses, with corporate lending kept near a 20% ceiling.
· Original article
IDEAYA coverage starts at William Blair with Outperform
IDEAYA coverage began with an Outperform rating in an October 16 update. William Blair later confirmed the company joined its expanded biotech research.
· Original article
Tango Therapeutics coverage starts with Outperform rating
Tango Therapeutics coverage began with William Blair’s Outperform rating on October 16, 2026. A later announcement confirms its broader biotech rollout.
· Original article
Revolution Medicines coverage starts at William Blair
Revolution Medicines coverage starts with an Outperform rating at William Blair, alongside positive ratings from Needham and RBC Capital.
Charts and market data by TradingView. Availability and delays vary by exchange.